BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in patients with HER2-negative gastric ...
A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations. This is an ASCO Meeting Abstract from ...
Development of a highly efficacious, first-in-class antibody-drug conjugate against a novel MUC1-C oncoprotein for metastatic colorectal cancer. Preliminary efficacy and safety of total neoadjuvant ...
Six months of chemotherapy in low-risk stage 3 colorectal cancer patients increases neuropathy compared to three months. IDEA collaboration found similar survival outcomes between three and six months ...
CHICAGO -- The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients who received immunotherapy in addition to adjuvant chemotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results